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Abstract
This report presents findings of a community survey of 3,021 adolescents and
young adults aged 14–24 years in Munich, Germany, carried out to determine
the prevalence of use and abuse of and dependence on ecstasy, amphetamines
and hallucinogens. The response rate was 71%. Results: (1) In 1995, 4% of the
male and 2.3% of the female respondents aged 14–24 reported the use of ecsta-
sy. Ecstasy-related substances (amphetamines and chemically related sub-
stances) were reported by 3.6% of men and 1.6% of women. Hallucinogens
were reported slightly less frequently by 3% of men and about 2% of women
(LSD combined with others). (2) Compared to findings from a 1990 survey
this constitutes a substantial, at least twofold, increase in consumption rate of
both types of substances. (3) Among lifetime users of both ecstasy and related
substances as well as hallucinogens about two thirds could be regarded as regu-
lar users. (4) The prevalence of DSM-IV abuse and dependence on ecstasy and
related substances is about 1%, identical to rates of hallucinogen abuse and
dependence. Findings also point to a significant dependence potential for both
substances. (5) Furthermore, considerable overlap between the two substances
was found. Conclusion: Our study suggests a substantial increase in both the
use of ecstasy and related substances as well as hallucinogens. The data further
suggest that the increase is strongest in younger age groups, but the risk of first
use of these substances continues to be present up to the age of 24 years. The
higher proportion of women contributing to this increase is noteworthy.
OOOOOOOOOOOOOOOOOOOOOO
Introduction
In most Western industrial countries reports in the
1990s have suggested increasing rates of stimulant use
among adolescents and young adults. One of this fairly
broad class of substances, the ‘designer drug’ ecstasy (also
named XTC, E or by hundreds of other street names) [1]
has gained particular attention in both the lay press as
well as among experts. This paper reports data on the use
of ecstasy and related substances as well as various forms
of hallucinogens, because the latter are not only frequently
chemically associated with certain types of drugs named
ecstasy, but also seem to be used concomitantly with
ecstasy.
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The term ‘ecstasy’ covers a considerable number of
fairly heterogeneous substances on the market. The most
frequent main active ingredients of ecstasy are the deri-
vates of the amphetamine molecule MDE (3,4-methylen-
dioxy-N-ethylamphetamine) and MDMA (3,4-methylen-
dioxy-N-methamphetamine). Furthermore, various other
derivates of the amphetamine molecule have been identi-
fied as active ingredients in substances sold under the
term ‘ecstasy’ in Germany and in other countries MDA
(3,4-methylendioxyamphetamine), MBDB (N-methyl-1-
(1,3-benzodioxol-5-yl)-2-butanamine) DOB (2,5-dime-
thoxy-4-bromamphetamine) [1]. Ecstasy is available in
tablet form under a wide heterogeneity of different
names, colors, weight and forms with a tremendous varia-
tion of active ingredients. Active dosages can range from
placebo to extremely high dosages or combinations with
other substances, mostly of other amphetamines and hal-
lucinogens. For the potential buyer neither the name nor
the weight and form of the tablet used allows reliable iden-
tification of the active ingredients. Although amphet-
amine and its derivates (similar to heroin and cocaine) are
classified among the so-called ‘hard drugs’, lay people and
people in the ecstasy scene widely regard this drug as a
‘safe drug’ without any risks of complications and no
dependence potential. This is in sharp contrast to numer-
ous reports of (a) several significant physiological effects
(loss of appetite, nausea, muscle ache, tachycardia, hypo-
thermia), (b) more severe cardiological and regulatory
complications), (c) psychological complications (anxiety,
panic attacks, recurrent acute paranoid psychotic experi-
ences, cognitive deficiencies and depression associated
with suicidal behavior) [2–7], (d) increasing number of
reports about ecstasy-related deaths [8, 9], and (e) severe
internal medical and psychiatric complications [3, 10].
Epidemiological evidence, however, about prevalence,
incidence and increasing rates of ecstasy and related sub-
stance use and disorders are quite meager in Germany as
well as in other countries. Reports refer mainly to ques-
tionnaire studies and selected observations, which do not
provide sufficiently reliable information about how large
and serious the problem is in the population. In 1995 the
Institute for Therapy Research, Munich [11], conducted a
telephone survey in a representative sample of 18- to 59-
year-olds (n = 2,023) and found that only 0.2% of the sam-
ple reported having used ecstasy at least once in their life-
time. Although rates among subjects aged 15- to 25-year-
olds were considerably higher, the rates nevertheless seem
to be a serious underestimate of the size of the problem.
Higher rates were reported by Hurrelmann [12] in a sur-
vey of adolescents in Northrhine-Westfalia in Germany in
which 0.8% of 12- to 17-year-olds reported having used
designer drugs and stimulants at least once. Indications
for a significant increase in the availability of ecstasy are
available from the statistics of the Federal Criminal
Office (BKA 1994, personal note), that reported consider-
able increases in confiscated ecstasy tablets from 1993 to
1994 of several hundred percent. Outside Germany, the
Institute for the Study of Drug Dependence (1992) [13]
reported an increase of 650% in ecstasy users in England
between the years 1990 and 1992, whereas no such
increase was found, for example, for heroin. More recent
data from the US among 8th, 10th and 12th graders in the
years 1994 to 1996 indicate that among 8th graders stimu-
lant use increased from 12.3 to 35%, among 10th graders
from 51 to 70.7%, whereas fairly stable rates were re-
ported between 1994 and 1996 for 12th graders with rates
ranging between 15.3 and 15.7%. Increases were also
reported for hallucinogens among 10th and 12th graders,
whereas rates for heroin, crack and cocaine showed no
great change [14]. For MDMA substances, the Monitor-
ing the Future Study [14] reported a sharp rise in the use
among college students and young adults during the
1990s. The percentage of users increased among 8th, 10th
and 12th graders from a low of 3.3% to a high of 6.1%.
Aims
The aim of the current study is to determine by stan-
dardized personal interviews the frequency of the use and
abuse of ecstasy and hallucinogens among 14- to 24-year-
old respondents in the greater Munich area. The focus of
the study is a detailed description of the type of substance
use as well as its frequency and the amount used. We will
also compare our data with a previous survey conducted
in 1990 with a comparable methodology, to examine the
increase of the use of ecstasy and related substances over
the years. Specifically, we will address the following ques-
tions:
1 How prevalent is the use of ecstasy, hallucinogens and
related substances?
2 What are typical patterns of use?
3 How prevalent is DSM-IV abuse and dependence of
ecstasy?
4 Is there an increase in the use of ecstasy?
5 What is the age of onset of ecstasy use?
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Methods
Design and Sample
Sampling and design of this study have been described elsewhere
in detail [15]. Briefly, data presented here are from the first wave of
the Early Developmental Stages of Psychopathology study (EDSP),
funded by the German Ministry of Research and Technology. The
study is designed to collect data on the prevalence, risk factors,
comorbidity and course of mental disorders with specific emphasis
on early developmental stages of mental disorders, including sub-
stance use disorders. The overall design of the study is prospective,
consisting of a baseline survey and two follow-up surveys at approxi-
mately 15 and 30 months after the baseline. Separate face-to-face
interviews with the respondents’ parents have also been carried out.
The follow-up assessments investigate symptom and syndrome pro-
gression, incidence and remission as well as helpseeking and the
development of impairments. The assessment of drug use is based on
the drug module of the M-CIDI, supported by memory aids to identi-
fy the type and content of the named substance. The EDSP commu-
nity sample includes 3,021 subjects aged 14–24 years at the time of
the baseline investigation, conducted in 1995.
To estimate the increase in drug use data were used from the Ba-
varian Infratest-Biogram-Study 1990 [16], which is comparable with
regard to sampling and questions used for assessing drug use. This
study was commissioned by the Bavarian Ministry of Work and
Social Affairs with emphasis on a representative sample of young
community members of the city of Munich and its rural surround-
ings in 1990. In total, 2,105 persons aged between 14 and 25 years
participated in this study in 1990.
Assessment of Substances
The wide range of names used for ecstasy as well as the user’s lack
of precise knowledge about the chemically active ingredients makes
the assessment quite difficult. Just asking for ‘ecstasy’ might lead to
an underestimation of its use. Therefore, we assessed respondents
capable of making reasonably clear indications about specifically
using ecstasy and also those using other terms or other types of stimu-
lants likely to be ecstasy-like substances. Thus, the expression ‘ecsta-
sy’ is used throughout this paper if the person has undoubtedly used
ecstasy. If the interviewed subject was not quite sure, but convinced
that the substance belonged to the group of ecstasy-like stimulants,
respondents were grouped under ecstasy-related substances and am-
phetamines. As a result we will report data on ecstasy alone as well as
data about related substances. The same procedure was applied to
hallucinogens, by separating LSD use from other hallucinogens,
although the reliability of these reports did not pose such serious
problems in our study.
Statistical Methods
Diagnoses of abuse and dependence are computed by the M-
CIDI-DSM-IV-diagnostic algorithm [17]. Analyses are based on
weighted data to reflect the different probability of each subject to be
selected for inclusion as well as to adapt for nonresponse. (For more
detailed information see [15].) Group differences were tested by
using the ¯2. Age-dependent odds ratios for the first use and first
appearance of abuse and dependence features were estimated by
Hazard rates.
Results
How Prevalent Is the Use of Ecstasy and Related
Substances as well as Hallucinogens in Adolescents
and Young Adults in 1995?
Table 1 reports the weighted prevalence rates for use of
ecstasy and hallucinogens and related substances in 14- to
24-year-old respondents of Munich in 1995. Included are
all persons who had tried the substances at least once in
their lifetime. The figure differentiates between (a) re-
spondents who were sure about having used ecstasy or
LSD, and (b) probands who did not explicitly use the
terms ‘ecstasy’ or ‘LSD’ but had used other, related sub-
stances (such as speed or amphetamines), or other halluci-
nogens (mescaline, peyote, psiloybin).
In 1995, 4% of men and 2.3% of women reported hav-
ing used ecstasy at least once in their life. Lifetime use of
other amphetamines was only slightly lower (3.5% men
and 1.6% women). LSD had been used by 2.8% of men
and 1.4% of women. Other hallucinogen use was reported
by 1.2% of respondents (lifetime). Across age groups there
are significant gender differences for the use of ecstasy
(¯2 = 7.46, p = 0.006), related substances (¯2 = 11.78, p =
0.001) and LSD (¯2 = 6.92, p = 0.009). No significant dif-
ference was found for the use of other hallucinogens,
although women show only half the use rates as compared
to men.
Use rates in men for ecstasy and related substances
increase steadily with age, from fairly low rates of 0.4% in
14- to 15-year-olds to a high of 7.6% in 22- to 24-year-
olds. For LSD and other hallucinogens use rates peak
among 18- to 19-year-olds with slightly lower rates among
respondents older than 20 years.
It should be noted that there is also considerable over-
lap in the use of these two substances. Only 2.6% of the
users consumed exclusively ecstasy (table 2); 97.4% of all
lifetime ecstasy users use or have used also cannabinoids,
58.9% cocaine, 48.2% related substances, 46% halluci-
nogens and 26.2% opiates.
How Prevalent Are Clinically Significant
Amphetamine- and Hallucinogen-Related Substance
Use Disorders?
Table 3 shows that 0.8% of the sample fulfilled the
diagnostic criteria for a DSM-IV amphetamine-related
substance use disorder with 0.4% qualifying for abuse and
0.4% for dependence (with or without abuse). This indi-
cates that every fifth ecstasy/amphetamine user between
the ages of 14–24 years is developing a clinically relevant
substance use disorder. 0.6% of the respondents fulfilled
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Table 1. Lifetime prevalences for the
use of ecstasy, related substances, LSD and
other hallucinogens
Age groups
14–15
%1
16–17
%1
18–19
%1
20–21
%1
22–24
%1
total
%1
Ecstasy men 0.2 3.5 3.3 5.1 5.6 4.0
women 0.0 2.5 2.0 1.8* 3.5 2.3*
total 0.1 3.0 2.6 3.3 4.5 3.1
Related men 0.2 1.3 4.4 4.2 5.3 3.5
substances2 women 0.2 1.4 1.1* 1.8 2.3* 1.6*
total 0.2 1.3 2.7 2.9 3.8 2.5
Total men 0.4 3.8 4.7 6.7 7.6 5.3
amphetamines women 0.2 3.0 2.0 2.8* 4.8 3.0*
total 0.3 3.4 3.3 4.6 6.2 4.1
LSD men 0.5 1.2 4.3 3.0 3.8 2.8
women 0.0 2.2 2.0 1.1 1.6* 1.4*
total 0.2 1.7 3.1 2.0 2.7 2.1
Other men 0.0 0.4 0.9 3.4 2.3 1.6
hallucinogens3 women 0.2 0.5 1.8 0.7* 0.9 0.8
total 0.1 0.5 1.4 2.0 1.6 1.2
Total men 0.5 1.9 4.3 6.0 4.7 3.7
hallucinogens women 0.4 3.3 3.4 1.5* 2.6 2.2*
total 0.4 2.6 3.8 3.6 3.6 3.0
* p ! 0.05 (gender difference).
1 Weighted.
2 Such as speed, amphetamines.
3 Such as mescaline, peyote, psilocybin, DMT.
Table 2. Use of other substances by lifetime ecstasy users
% among ecstasy users reporting
other substance groups
men women total
Cannabinoids1 98.8 95.0 97.4
Opioids2 24.3 29.4 26.2
Cocains3 61.0 55.3 58.9
Hallucinogens4 50.3 38.5 46.0
Related substances5 54.0 38.0 48.2
1 Cannabis, hashish.
2 Heroin, opium, methadone, morphium.
3 Cocaine, coca leaves, crack.
4 LSD, mescaline, peyote, psilocybin, DMT.
5 Amphetamines, khat, betel nut, speed.
Table 3. Lifetime prevalence of DSM-IV abuse or dependence on
ecstasy, related substances, LSD and other hallucinogens
Men
%
Women
%
Total
%
Ecstasy and related substances
Abuse 1.2 0.3 0.8
Abuse without dependence 0.8 0.0 0.4
Dependence 0.4 0.4 0.4
LSD and other hallucinogens
Abuse 0.9 0.3 0.6
Abuse without dependence 0.6 0.0 0.3
Dependence 0.3 0.4 0.4
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Fig. 1. Frequency of ecstasy and related substance use among reg-
ular users.
Fig. 2. Increase of the use of ecstasy and related substances, LSD
and other hallucinogens between 1990 and 1995 in Munich.
DSM-IV criteria for abuse (0.4%) or dependence (0.3%)
of hallucinogens, indicating that 1 of 4 male lifetime users
and 1 of 8 female users develop abuse or dependence, or
both, of this type of substance.
Pattern of Use
For the purpose of this study we define subjects who
used a substance once in their life as ‘experimental users’
and subjects with a use of about 2–4 times as ‘nonregular
users’. Subjects who have used a substance at least 5 times
are defined as ‘regular users’. Among all lifetime users
24.2% had used ecstasy or related substances and 30.3%
LSD or hallucinogens just once up to the point of our
investigation. Nonregular use was reported by 35.2% (ec-
stasy or related substances) and 25% (LSD or hallucino-
gens). Regular users form the largest group with 47.3% of
the ecstasy or related substance users and 44.7% of the
LSD or hallucinogen users.
Figure 1 shows the frequency of use of ecstasy or
related substances among regular users. Only 3% used the
substance every day and 14% three to four times a week.
Most of the users (63%) used ecstasy or related substances
once or twice a week or one to three times a month. Quite
similar to almost identical patterns were reported for hal-
lucinogens (not reported in figure 1).
Was There an Increase in Use from 1990 to 1995:
Evidence for Age Cohort Specific Increases
Figure 2 shows that the 1995 lifetime use prevalence
rates for ecstasy and related substances as well as for hal-
lucinogens are at least 2 times higher than those found in
1990. Men seem to show a steeper increase in the use of
LSD/other hallucinogens (1.3–3.8%) and ecstasy or relat-
ed substances (2–5.2%) than women (1.3–2.3%; 2–3%).
In summary, in 1995 men had about three times and
women had about twice the rate for use of these sub-
stances they had in 1990.
In our study, the subjects were asked about the age they
used each type of substance for the first time in their life.
Figure 3 shows relatively dissimilar birth-cohort-specific
cumulative hazard estimates of ecstasy or related sub-
stances, and LSD or hallucinogen use. The younger birth
cohort reports a significantly earlier and considerably
more frequent use of ecstasy as well as hallucinogens up to
the age of 17 years, compared to the older cohort. The
age-of-first-use curve among respondents born between
1971 and 1976 shows a slow but steady increase for ecsta-
sy use up to the age of 24 years: for hallucinogens this
increase levels off after the age of 22 years.
Discussion
Unlike previous German studies investigating the
prevalence of ecstasy and hallucinogen use by self-report
questionnaires, the results of the present study are based
on standardized personal interviews in a representative
community sample of 3,021 subjects from the greater
Munich area. Furthermore, the assessment is based on a
standardized, internationally compatible diagnostic inter-
view, the M-CIDI, providing detailed and standardized
information on patterns of use, diagnosis of abuse and
dependence according to DSM-IV criteria, along with
information about the onset of use and duration.
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Fig. 3. Cohort effects of the age of onset
of ecstasy and related substances, LSD and
hallucinogens use.
Nevertheless, despite these advantages over earlier
studies some limitations need to be taken into account.
(1) It is relatively complicated to get reliable and valid
information about the specific chemical structure of the
substances used. The terms ‘ecstasy tablets’ or ‘designer
drug’ alone usually do not allow the determination of
what type of substance was actually used because of the
extreme heterogeneity and variability of active ingre-
dients in the tablets. Although we tried to assess this issue
in more detail, it became evident that detailed and exact
information about dosages and the quality of the sub-
stance used might only be feasible when such studies in
the future are combined with specific pharmacological
assays. Obviously, however, most of our respondents’
descriptions suggest that ecstasy and related drugs often
consist of a mixture of metamphetamine and hallucino-
genic components, not allowing us to make a clear distinc-
tion between ecstasy in its strict sense and hallucinogens.
(2) The data reported focus exclusively on 14- to 24-
year-olds in the metropolitan area of Munich that is usual-
ly considered by experts to be a fairly low-prevalence area
compared to other metropolitan areas such as Hamburg
and Berlin with regard to drug use. Thus, the reader
should take into account that the reported prevalence
rates cannot be used to estimate the size of the problem
throughout Germany. We can expect that rates from other
metropolitan cities are considerably higher, whereas rates
from more rural areas might be considerably lower.
(3) In this article we focus specifically on determining
the size of the present problem as well as the question
whether ecstasy and hallucinogen use is on the rise. At the
same time we do not report more detailed findings with
regard to the associated risks and complications as well as
the type of dependence and abuse patterns found in our
study. This type of data will be made available as soon as
the subsequent wave of reexamination becomes available,
together with information about the stability, the remis-
sion and the progression of these patterns of use.
(4) Furthermore, the base rates of our study are fairly
low, not allowing us to describe physical and psychologi-
cal short- and long-term effects of the use of these sub-
stances in detail. A recent report by Thomasius et al. [7]
has comprehensively reviewed the various complications
reported for ecstasy and related substances.
In summary, regular ecstasy users in pure form are
very rare because of the remarkable overlap between sub-
stances used. The results rather show that 97.4% of all
lifetime ecstasy users also use cannabinoids, 58.9% co-
caine, 48.2% other substances, 46% hallucinogens and
26.2% opiates. Furthermore, in spite of the above-men-
tioned limitations, our study clearly supported the hy-
pothesis that there has been a considerable increase in the
use of ecstasy, related substances as well as hallucinogens.
Compared to a similar regional review conducted in 1990
in the Munich area [16], the prevalence of use of ecstasy
has been found to be three times higher in men and two
times higher in women. Such an increase is also supported
by other sources, such as the increasing rate of confiscated
ecstasy substances by the German police (BKA) as well as
a more recent survey of the Institute for Therapy Re-
search [18]. Further evidence for a considerable increase
in the use of ecstasy and hallucinogens also comes from
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our age cohort analysis. Younger birth cohorts show con-
siderable and highly significant higher cumulative inci-
dence lifetime rates and, furthermore, the age of onset for
the first use of these substances has been found to be con-
siderably lower in younger birth cohorts compared to old-
er cohorts. This is strong evidence for a continuing ‘ecsta-
sy’ epidemic. By extrapolating the use rates for the young
cohorts we can assume that use rates will at least double
over the course of the next 2 years. In addition, our data
also suggest that the increasing rates after the age of 17
years can be expected to contribute to further increasing
rates of ecstasy and related substance use. Obviously, the
attractiveness of ecstasy and related substances continues
to be high even among people in their twenties, a trend is
not apparent in a similar way for hallucinogens. For the
latter we find increasing rates among respondents up to
the age of 19 years, but after this age only few new cases
report the first use of hallucinogens. These findings com-
pare well with more recent reports from the National
Comorbidity Survey [19, 20].
Both ecstasy as well as hallucinogens seem to be almost
always used as weekend drugs, whereas the daily or
almost daily use of these types of substances is the excep-
tion rather than the rule. However, daily use is frequent
among those with a dependence syndrome. This supports
the typical ‘scene’ description [7] that links the use of
ecstasy and related substances to rave parties and other
music and socially related activities.
Ecstasy as well as hallucinogens are frequently per-
ceived by the users as so-called ‘safe drugs’ with no addic-
tion potential, although this does not match the experts’
view that classify these substances as so-called ‘hard
drugs’ because of their chemical properties. Our data sup-
port the latter, because of a serious substance disorder risk
potential by these types of substances among lifetime
users. Every fifth person having used either sort of sub-
stance at least once is likely to fulfil criteria for the abuse
of or dependence on this substance later on. These find-
ings are remarkable, given the young age of our respon-
dents as well as the short period of use reported by the vast
majority of our respondents. Future research should ex-
amine in more detail whether this high substance disorder
potential is due to specific compounds of ecstasy and hal-
lucinogens, whether it is related to the concomitant use of
other substances or to the fact that both of these sub-
stances often contain other ingredients that contribute to
this high substance disorder risk potential.
The reasons for this increase in the use of both ecstasy
and hallucinogens are at this point not easy to identify. In
an earlier publication by Schuster and Wittchen [1], we
suggested that the availability as well as the increasing
popularity of the rave scene are probably among the most
important factors contributing to the observed ecstasy
and hallucinogen epidemic. Why, however, people who
have tried ecstasy and hallucinogens for the first time con-
tinue to use them, which is true for almost two thirds of
our respondents, is less clear. In the above-mentioned
publication we studied the different motivational patterns
for use and continued use in more detail, suggesting that
the lack of knowledge or awareness about the risks of
severe adverse effects or the risk of becoming dependent
on these drugs might be important factors. The evaluation
of this issue remains to be complicated because we also
have shown that motivation patterns for first use differ
considerably from those for continued use [1]. One key
finding in this context was that after some time many
users of ecstasy do not find the effects of ecstasy attractive
enough anymore and turn to mixtures containing halluci-
nogens or directly demand hallucinogens. This switch
from ecstasy-like substances to hallucinogens is also sup-
ported by our age-of-onset analysis that suggests that hal-
lucinogen use is usually secondary to ecstasy use. As this
study indicates that also a multiple use of substances in
combination to ecstasy becomes very common in adoles-
cents and young adults, it is noteworthy that further inves-
tigations are necessary.
To conclude, our representative community survey
clearly supports previous reports about a considerable
increase in the use of both ecstasy-like substances as well
as hallucinogens. This ongoing and obviously continuing
increase should be a serious concern from a public health
perspective and stresses the need for the designation of
specific prevention activities. A critical issue in designing
such preventive trials will probably be to design activities
aimed at a reduction in first-time users by giving informa-
tion about the adverse effects of these substances and the
associated risks, as well as preventive actions for the regu-
lar user. For the latter there seems to be a considerable
need for information about the association with halluci-
nogen as well as the additional risk associated with the
concomitant use of both types of substances, in order to
prevent the progression from initial stages of use on to
abuse and dependence. Our upcoming 5-year follow-up
investigation will probably allow us to provide the scien-
tific community with more specific information about the
further development of this cohort and will also be able to
identify those factors associated with progression and
remission for ecstasy-like hallucinogenic substances and
the multiple use of other substances in combination with
ecstacy.
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